Intelon Optics® is a medical device company focusing on the development and commercialization of their Brillouin Optical Scanner System (BOSSTM). Using non-contact point-by-point capture, this revolutionary device provides new and useful diagnostic data by understanding the structure of ocular tissues extending from the cornea to the posterior part of the globe. BOSS works by using light energy to measure reverberations through a depth of the ocular tissue.
BOSS brings a wide range of novel diagnostic and surgical solutions to empower eye care professionals with confident decision-making and control based on biomechanical tissue properties of the eye.
The biomechanics, or biomechanical properties, are primary and critical factors directly impacting the functionality of the eye as a refractive system. They affect functional responses of the cornea and the crystalline lens to light and greatly impact vision.
The company’s commercial focus begins with refractive surgery and extends to other diagnostic and surgical areas in eye care. Intelon’s products will bring revolutionary solutions to allow data-driven surgical outcomes, control of treatment results, and a high level of decision-making confidence to clinicians and surgeons based on biomechanical tissue properties relevant to correction of refractive errors.
To date, BOSS is the only technology allowing in-vivo, localized measurement of Young’s modulus, a direct measure of the stress-strain relationship of ocular tissues influencing the refractive performance of the eye.
Those solutions will eventually be offered to a broad range of customers, ranging from health care providers to research facilities in a multitude of international markets, and as OEM solutions to multinational corporations. Intelon Optics is headquartered in Boston, Massachusetts, is in the clinical phase, and is currently seeking Series B funding. Current investors are Kakao Ventures, IMM Investment, Mirae Asset Venture, InterVest and Luminate.